Conditional marketing authorization has been granted to the CD20xCD3 T-cell engaging bispecific antibody mosunetuzumab (Lunsumio) by the European Commission for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies, according to Roche.1
The basis of the approval is supported by findings of the phase 1/2 GO29781 trial (NCT02500407), which met its primary end point of complete response (CR) per independent review facility (IRF) assessment in 2021, with the bispecific antibody eliciting a CR rate of 60% (95% CI, 49%-70%) at a median follow-up of 18.3 months.
Further data revealed the overall response rate (ORR) achieved with the agent to be 80% (95% CI, 70%-88%), and that the median duration of response (DOR) was 22.8 months (95% CI, 9.7not estimable [NE]). Along with this, favorable tolerability was seen in patients with heavily pretreated follicular lymphoma who received mosunetuzumab.
We are delighted that Lunsumio is the first bispecific antibody approved in Europe for people with relapsed or refractory follicular lymphoma, said Levi Garraway, MD, PhD, Roches chief medical officer and head of global product development, in the press release. Lunsumios high response rates, off-the-shelf availability, and initial outpatient administration could transform how advanced follicular lymphoma is treated.
Within the multicenter, open-label, dose-escalation, and dose-expansion trial, mosunetuzumab was examined in patients with follicular lymphoma with grade 1 to 3a disease.2
Eligibility in the trial was open to patients with an ECOG performance status of 0 to 1 and to those who had previously received 2 or more systemic regimens, including at least 1 anti-CD20 antibody and 1 alkylating agent.
Every 3 weeks, as part of 21-day cycles through a step-up dosing approach in cycle 1, patients (n = 90) were administered mosunetuzumab. Within the first cycle, patients received mosunetuzumab at a dose of 1 mg on day 1, 2 mg on day 8, and 60 mg on day 15. For cycle 2, mosunetuzumab was given at a dose of 60 mg on day 1. In subsequent cycles, the bispecific antibody was given at 30 mg on day 1. For the patients who achieved a CR following cycle 8, they were subjected to 17 cycles of treatment. Additionally, there was no mandatory hospitalization for participants given the initial dose.
The primary end point of the trial was CR rate per IRF assessment, evaluated in comparison with the historical CR rate of 14%, and secondary end points included ORR, DOR, progression-free survival (PFS), safety, and tolerability.
Of those enrolled in the study, the median age was 60 years (range, 29-90) with 61.1% being male. Patients with an ECOG performance status of 0 made up 58.9% of the participants while 41.1% had a status of 1. A total of 23.3% of patients had stage I-II Ann Arbor disease, and 76.7% had stage III-IV disease. Additionally, those enrolled in the trial mostly had received 3 prior lines of therapy (range, 2-10), and all patients had previously received anti-CD20 therapy and an alkylator.
Other prior systemic therapies patients received consisted of PI3K inhibitors (18.9%), immunomodulatory drugs (14.4%), and chimeric antigen receptor (CAR) T-cell therapy (3.3%). Patients who had previously had autologous stem cell transplant made up 21.1% of participants.
Moreover, 68.9% of individuals were refractory to the last prior therapy they received, 78.9% of patients were refractory to a previous anti-CD20 therapy, and 53.3% were double refractory to an anti-CD20 therapy as well as an alkylating therapy. A total of 52.2% of patients also had progression of disease within 24 months (POD24) of starting treatment.
Data presented at the 2021 ASH Annual Meeting revealed that mosunetuzumab had an investigator-assessed CR rate of 60% (95% CI, 49%-70%), and the CR rates produced with the agent in high-risk subgroups were similar to that of the overall study population.
Patients younger than 65 years of age (n = 60) had a CR rate with the bispecific antibody of 55% (95% CI, 42%-68%) compared with a CR rate of 70% (95% CI, 51%-85%) in patients aged 65 years or older (n = 30). With the agent, the CR rate was 74% (95% CI, 56%-87%) for those who previously received 2 lines of therapy (n = 34) and 52% (95% CI, 39%-65%) in patients who received 3 or more prior lines (n = 56). Patients who were relapsed or refractory to their last prior therapy (n = 62) and in those who were not (n = 28) demonstrated CR rates of 52% (95% CI, 39%-65%) and 79% (95% CI, 59%-92%), respectively.
Mosunetuzumab also produced a CR rate of 50% (95% CI, 35%-65%) in the group of individuals who were double refractory (n = 48) vs 71% (95% CI, 55%-84%) in those who were not. Further, the CR rate was shown to be 57% (95% CI, 42%-72%) for those with POD24 disease (n = 47) compared with 63% (95% CI, 47%-77%) in those who did not progress within 24 months (n = 43).
Median time to response was 1.4 months (range, 1.1-8.9), and the median time to first CR was 3.0 months (range, 1.1-18.9). The median PFS with mosunetuzumab was 17.9 months (95% CI, 10.1-NE).
In regard to safety, cytokine release syndrome (CRS) was the most common toxicity, which was observed in 39% of patients. Still, CRS was low grade with 14% of patients experiencing grade 2 CRS, and it was resolved by treatment completion. Other frequently observed adverse effects included neutropenia, hypophosphatemia, pyrexia, and headache.
Two phase 3 clinical studies are exploring the use of mosunetuzumab in the second-line setting: CELESTIMO (NCT04712097), investigating mosunetuzumab plus lenalidomide (Revlimid) for patients with follicular lymphoma, and SUNMO (NCT05171647), investigating mosunetuzumab plus polatuzumab vedotin (Polivy) for patients with diffuse large B-cell lymphoma.
Having additional treatment options for people with follicular lymphoma, where multiple prior lines of therapy have failed, is critical to help them achieve better outcomes, Elizabeth Budde, MD, PhD, a hematologic oncologist and associate professor at the City of Hope Comprehensive Cancer Center, added in the press release. It is exciting to have a new class of immunotherapy like Lunsumio, offering a readily available, chemotherapy-free and fixed-duration treatment, with great potential to provide durable remissions without the need to stay on treatment continuously.
- Unable to find a partner for stem cell therapy, Gamida accepts sale to investment firm to survive - Fierce Biotech - March 28th, 2024
- Putting Stem Cell-Based Therapies in Context - National Institutes of ... - January 31st, 2024
- Global Stem Cell Therapy Industry Outlook to 2028, Driven by Therapeutic Innovations and Clinical Advancements ... - Yahoo Finance - January 31st, 2024
- Stem Cell Transplant and CAR T-cell Therapy: The Patient and Care Partner Experience | BMT Infonet - BMT Infonet | - January 31st, 2024
- New study on promising stem cell-based therapy for Crohn's disease - Medical Xpress - January 31st, 2024
- The Trouble With Stem Cell Therapy - Consumer Reports - December 20th, 2023
- Stem Cell Therapy Boosts Quality of Life for People With Advanced Heart Failure - MedicineNet - December 20th, 2023
- The stem cell therapy project Blue4Therapy brought to a highly successful close - Marketscreener.com - April 7th, 2023
- Stem Cell Therapy for Spinal Cord Injury - PubMed - December 27th, 2022
- How much does stem cell therapy cost in 2022? - The Niche - December 18th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - December 18th, 2022
- Ethical issues in stem cell research and therapy - December 10th, 2022
- EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator Initiated Trial for ET-01, its Investigational Gene Editing... - November 6th, 2022
- Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood... - October 21st, 2022
- Global Cell Culture Protein Surface Coating Market to Grow at a CAGR of 13.82% During 2022-2031; Market to Expand on the Back of the Technological... - October 21st, 2022
- Stem Cell Therapy for Knees - thriveMD Denver & Vail, CO - October 13th, 2022
- Stem cell therapy and autism | Raising Children Network - October 13th, 2022
- Cellectis Presents Data on Two TALEN-based Gene Therapy Preclinical Programs for Patients with ... - The Bakersfield Californian - October 13th, 2022
- Global Nerve Repair and Regeneration Devices Market to Reach $12.9 Billion by 2027 - Yahoo Finance - October 13th, 2022
- 2023 to be highly lucrative for drug developers across therapeutic areas: Report - BSI bureau - October 13th, 2022
- Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and ... - October 4th, 2022
- Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the... - October 4th, 2022
- Innovative Imaging Techniques to Accelerate the Discovery of New... - Healthcare Tech Outlook - October 4th, 2022
- Celtic-mad dad left unable to talk after horror attack as family fundraise for stem cell therapy... - The Scottish Sun - September 25th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - Benzinga - September 16th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire - September 16th, 2022
- Radical lupus treatment uses CAR T-cell therapy developed for cancer - New Scientist - September 16th, 2022
- Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with... - September 16th, 2022
- T-Cell Redirection Therapy Shows Promise As Salvage Therapy in R/R Multiple Myeloma - Targeted Oncology - September 16th, 2022
- Orca Bio expands manufacturing capabilities to take cell therapies through to commercialization - BioPharma-Reporter.com - September 16th, 2022
- BioRestorative Therapies : BRTX Presentation September 2022 - Marketscreener.com - September 16th, 2022
- Advanced cellular therapy brings hope to KSA cancer patients - Omnia Health Insights - September 16th, 2022
- IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400 - BioSpace - September 16th, 2022
- The five hottest private biotech companies in India - Labiotech.eu - September 16th, 2022
- Be The Match and William G. Pomeroy Foundation Announce $500k Gift and Matching Campaign - PR Newswire - September 16th, 2022
- California man appears to be another person cured of HIV after a stem cell transplant - aidsmap - August 5th, 2022
- Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies - PR... - August 5th, 2022
- Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 - Benzinga - August 5th, 2022
- The Role of Cell Banking Outsourcing Market Industry Growth, Competitors Analysis, New Technology, Trends and Forecast 2020 2030 - Digital Journal - August 5th, 2022
- World to Witness Surging Use of Neurostimulation & Neuromodulation Devices for Nerve Repair and Regeneration, Predicts Fact.MR - GlobeNewswire - August 5th, 2022
- Dr. Owhofasa Agbedia Honored With The 2022 ASH-CIBMTR-ASTCT Career Development Award - Business Wire - August 5th, 2022
- Novel Drug-Chemotherapy Combo After Stem Cell Transplant Associated With 'Favorable Survival Outcomes' in Group of Rare Blood Cancers - Curetoday.com - July 27th, 2022
- Broadening access to cancer fighting therapy led by UH researcher | University of Hawaii System News - University of Hawaii - July 27th, 2022
- Petition calling for 'life-changing' MS treatment funding handed to Parliament - Stuff - July 27th, 2022
- How effective is stem cell therapy for liver cirrhosis? - Times of India - July 27th, 2022
- Kite's CAR T-cell Therapy Tecartus Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL) - Gilead Sciences - July 27th, 2022
- S'porean doctor, a sought-after top expert in cell therapy, appointed to WHO expert panel - The Straits Times - July 27th, 2022
- Top 10 Advances in Large B-Cell Lymphomas in the Past 10 Years - Targeted Oncology - July 27th, 2022
- Stem Cell Therapy Market Emerging Trends to Make Driving Growth on Key Players Status - Taiwan News - July 19th, 2022
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 11th, 2022
- Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal - July 11th, 2022
- Diabetic foot treatment: Here's all you need to know about stem cell therapy - Hindustan Times - July 11th, 2022
- Every 5 minutes someone in India is diagnosed with blood cancer or a blood disorder: Patrick Paul, CEO, DKMS BMST Foundation India - The Financial... - July 11th, 2022
- Growing Prevalence & Recurrence Of Rheumatoid Arthritis Is Expected To Growth Of The Rheumatoid Arthritis Stem Cell Therapy Market Designer Women... - July 11th, 2022
- New sickle cell disease gene therapies depend on getting the right mouse - EurekAlert - July 11th, 2022
- Market Share, Supply, Analysis and Forecast of Human Insulin Drugs and Delivery Devices to 2026 Designer Women - Designer Women - July 3rd, 2022
- Gamida Cell Submits Biologics License Application for Omidubicel to the FDA - Pharmacy Times - June 22nd, 2022
- Global Rheumatoid Arthritis Stem Cell Therapy Market 2022 Swot Analysis by Top Key Vendors, Demand And Forecast Research to 2028 Designer Women -... - June 22nd, 2022
- Stem Cell Therapy in Jacksonville at Pangenics Regenerative Center - June 13th, 2022
- Stem-Cell Based Therapy Shows Promise in Treating High-Risk Type 1 Diabetes - Newswise - June 13th, 2022
- What Is Myelofibrosis? Symptoms, Causes, Diagnosis, Treatment, and Prevention - Everyday Health - June 13th, 2022
- Global Human Embryonic Stem Cell Market To Be Driven By The Rapid Technological Advancements In The Forecast Period Of 2022-2027 The Greater... - June 4th, 2022
- Pancreatic Cancer Therapy Experiment Saves Woman; Is It A Breakthrough? - Kaiser Health News - June 4th, 2022
- Dedication, Achievement and Grace in Cancer Care - Curetoday.com - June 4th, 2022
- Nerve Repair and Regeneration Market worth $11.6 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance - June 4th, 2022
- Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis - DocWire News - June 4th, 2022
- CPX-351 in Treatment of AML and Clinical Considerations - OncLive - June 4th, 2022
- High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study - AJMC.com Managed Markets Network - June 4th, 2022
- JASPER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - May 15th, 2022
- Cell Culture Market to Gain US$ 27.6 Bn by 2031, Burgeoning Demand for Biosimilars and Biologic Therapeutics Fueling Market Growth - BioSpace - May 15th, 2022
- Pilot Study Shows Promising Results With CPX-351 in Relapsed/Refractory ALL - OncLive - May 15th, 2022
- Primary Cell Culture Market Mechanical Separation Segment Is Expected To Witness A Lucrative CAGR Of 11.7 - Benzinga - May 15th, 2022
- Vale man with MS needs 50,000 for treatment in Mexico - Evesham Journal - May 2nd, 2022
- Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO... - May 2nd, 2022
- Long-Term Axi-Cel Data 'May Be Suggestive of a Cure' in Patients With Large B-Cell Lymphoma - Curetoday.com - May 2nd, 2022
- Billy Connolly donates painting to Glasgow woman diagnosed with cancer five times - Glasgow Times - May 2nd, 2022
- The Progress Made in Stem Cell Therapy, Regenerative Medicine: Peter J. McAllister, MD, FAAN - Neurology Live - April 19th, 2022
- AACR: Resistance Mechanisms to CAR-T Cell Therapy ID'd in ALL - HealthDay News - April 19th, 2022
- 2022-04-18 | NDAQ:BRTX | Press Release | BioRestorative Therapies Inc - Stockhouse - April 19th, 2022
- First Patient With Lymphoma Receives Novel Cell Therapy in Large-Scale Trial - Curetoday.com - April 6th, 2022